Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 5
Author: ICICI Securities Limited

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	28 Jun 2025	Dr. Reddy's Labs	Consensus Share Price Target	1301.00	1268.74	-	-2.48	hold	pdf Detailed Estimates
	27 Jan 2023	Dr. Reddy's Labs	ICICI Securities Limited Target	1301.00	5131.00	4200.95 (-69.03%)	Target met	Buy	pdf post cache	Broker Report Revlimid springs a surprise, again! ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q3FY23 reported performance exceeded our and consensus estimates, largely driven by higher-than-estimated sales of Revlimid in Q3FY23. This resulted in 27.3% YoY growth in revenue to Rs67.7bn (I-Sec: Rs58.6bn). pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2023	Dr. Reddy's Labs	Axis Direct Target	1301.00	5100.00	4314.00 (-69.84%)	Target met	Buy	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We recommend a BUY on the stock. pdf Copy Link Share on Share on Share on Share on Alert
	26 Jan 2023	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1301.00	4700.00	4200.95 (-69.03%)	Target met	Hold	pdf post cache	Broker Report Dr Reddy's Labs (HOLD): Strong US sales; recovery in EM and PSAI businesses BOB Capital Markets Ltd. Q3 revenue growth strong at 27% YoY to Rs 67.7bn, supported by US contribution and launches pdf Copy Link Share on Share on Share on Share on Alert
	26 Dec 2022	Dr. Reddy's Labs	Axis Direct Target	1301.00	4750.00	4248.60 (-69.38%)	Target met	Buy	pdf post cache	Broker Report Pick of the Week:26 DEC 2022 Axis Direct We recommend a BUY rating on the stock with a target price of Rs 4,750/share, implying an upside of 10% from the CMP. pdf Copy Link Share on Share on Share on Share on Alert
	01 Nov 2022	Dr. Reddy's Labs	Axis Direct Target	1301.00	5000.00	4535.30 (-71.31%)	Target met	Buy	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We recommend a BUY rating on the stock with a TP of Rs 5,000/share. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1301.00	4900.00	4535.30 (-71.31%)	Target met	Buy	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	ICICI Securities Limited Target	1301.00	5134.00	4459.95 (-70.83%)	Target met	Buy	pdf post cache	Broker Report Revlimid springs surprise; outlook intact ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY23 reported performance exceeded our and consensus estimates, largely driven by strong sales of Revlimid and recovery of US base and Russia sales. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	KRChoksey Target	1301.00	5200.00	4433.70 (-70.66%)	Target met	Buy	pdf post cache	Broker Report Revlimid boosts strong growth in revenues and margins for the quarter KRChoksey Dr. Reddy’s Laboratories reported revenue growth at 9.4% YoY (26.6% QoQ) to INR 63,318 mn driven by strong growth in the Global Generics (GG) segment. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	SMC online	1301.00		4555.65 (-71.44%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr Reddys Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	Motilal Oswal Target	1301.00	5180.00	4433.70 (-70.66%)	Target met	Buy	pdf post cache	Broker Report Russia recovers, while PSAI still a drag on earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

27.55% Gain from 52W Low

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1343.25. The consensus estimate represents an upside of 3.25% from the last price of 1301. View 21 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Revlimid springs a surprise, again!

Result Update:Dr Reddys Labs

Dr Reddy's Labs (HOLD): Strong US sales; recovery in EM and PSAI businesses

Pick of the Week:26 DEC 2022

Result Update:Dr Reddys Labs

DR REDDY'S LABS

Revlimid springs surprise; outlook intact

Revlimid boosts strong growth in revenues and margins for the quarter

Dr Reddys Laboratories

Russia recovers, while PSAI still a drag on earnings

Advisor Screeners